ES2624835T3 - Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos - Google Patents
Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos Download PDFInfo
- Publication number
- ES2624835T3 ES2624835T3 ES10806238.1T ES10806238T ES2624835T3 ES 2624835 T3 ES2624835 T3 ES 2624835T3 ES 10806238 T ES10806238 T ES 10806238T ES 2624835 T3 ES2624835 T3 ES 2624835T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 2639
- 239000000427 antigen Substances 0.000 claims abstract description 71
- 102000036639 antigens Human genes 0.000 claims abstract description 71
- 108091007433 antigens Proteins 0.000 claims abstract description 71
- 239000000178 monomer Substances 0.000 claims abstract description 62
- 230000027455 binding Effects 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 44
- 239000012634 fragment Substances 0.000 claims abstract description 38
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002773 nucleotide Chemical group 0.000 description 1160
- 125000003729 nucleotide group Chemical group 0.000 description 1160
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 782
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 782
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 775
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 757
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 756
- 239000003112 inhibitor Substances 0.000 description 43
- 230000002860 competitive effect Effects 0.000 description 22
- 238000002835 absorbance Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 10
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 7
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 7
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 7
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000028698 Cognitive impairment Diseases 0.000 description 5
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001235 sensitizing effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000007633 synaptic toxicity Effects 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000283953 Lagomorpha Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 102000046783 human APP Human genes 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282692 Catarrhini Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001554831 Hamadryas <angiosperm> Species 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 229940124438 antineurotoxic agent Drugs 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000007507 senile plaque formation Effects 0.000 description 2
- 208000022288 senile plaque formation Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23179709P | 2009-08-06 | 2009-08-06 | |
| US231797P | 2009-08-06 | ||
| US28253310P | 2010-02-26 | 2010-02-26 | |
| US282533P | 2010-02-26 | ||
| PCT/JP2010/004925 WO2011016238A1 (en) | 2009-08-06 | 2010-08-05 | Antibodies that specifically bind to a beta oligomers and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2624835T3 true ES2624835T3 (es) | 2017-07-17 |
Family
ID=43544147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10806238.1T Active ES2624835T3 (es) | 2009-08-06 | 2010-08-05 | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8858949B2 (enExample) |
| EP (1) | EP2462161B1 (enExample) |
| JP (1) | JP5769316B2 (enExample) |
| CN (1) | CN102574915B (enExample) |
| DK (1) | DK2462161T3 (enExample) |
| ES (1) | ES2624835T3 (enExample) |
| WO (1) | WO2011016238A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| US8906367B2 (en) * | 2007-01-05 | 2014-12-09 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| SG185316A1 (en) * | 2007-10-19 | 2012-11-29 | Immunas Pharma Inc | ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF |
| CA2714413C (en) | 2008-02-08 | 2017-01-24 | Immunas Pharma, Inc. | Antibody capable of binding specifically to ab-oligomer, and use thereof |
| JP2011527338A (ja) * | 2008-07-09 | 2011-10-27 | ユニバーシティー オブ チューリッヒ | 神経新生を促進する方法 |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| JP5812418B2 (ja) | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| ES2614949T3 (es) | 2009-08-06 | 2017-06-02 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos |
| SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
| KR102119187B1 (ko) | 2011-01-10 | 2020-06-08 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 줄기 세포 인자 억제제 |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| SI2694106T1 (en) | 2011-04-01 | 2018-04-30 | Immunogen, Inc. | Methods for increasing the effectiveness of treatment with FOLR1 receptor cancer |
| LT2723379T (lt) | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
| GB201110938D0 (en) * | 2011-06-27 | 2011-08-10 | Iti Scotland Ltd | Compounds |
| WO2013040472A2 (en) * | 2011-09-16 | 2013-03-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to dna damage repair |
| US9200073B2 (en) * | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| EP3036005A4 (en) * | 2013-08-21 | 2017-04-26 | The Board Of Regents Of The University Of Texas System | Compositions and methods for targeting connexin hemichannels |
| CA3222465A1 (en) | 2013-08-30 | 2015-03-05 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| WO2015054600A2 (en) * | 2013-10-10 | 2015-04-16 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2015065987A1 (en) * | 2013-11-01 | 2015-05-07 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| JP2017512056A (ja) * | 2014-02-10 | 2017-05-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ヒト・タウに結合する抗体および該抗体を使用してヒト・タウを定量するためのアッセイ |
| EP3119805A1 (en) | 2014-03-20 | 2017-01-25 | Wellstat Diagnostics, LLC | Antibodies and methods for the detection of cell death |
| SG11201607258SA (en) * | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
| KR102050082B1 (ko) | 2014-08-19 | 2019-11-29 | 머크 샤프 앤드 돔 코포레이션 | 항-tigit 항체 |
| CA2959179A1 (en) | 2014-09-16 | 2016-03-24 | Ovascience, Inc. | Anti-vasa antibodies, and methods of production and use thereof |
| JP2017536102A (ja) * | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| IL278574B2 (en) | 2014-11-12 | 2024-11-01 | Seagen Inc | Glycan-interacting compounds and methods of use |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| WO2016097420A1 (en) * | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
| SG11201705986QA (en) * | 2015-01-29 | 2017-08-30 | Technophage Investigação E Desenvolvimento Em Biotecnologia Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| EP3262070A4 (en) * | 2015-02-24 | 2018-07-25 | Rpeptide, LLC | Anti-amyloid-beta antibodies |
| WO2016145022A1 (en) * | 2015-03-11 | 2016-09-15 | The Board Of Regents Of The University Of Texas System | Anti-dc-hil antibodies for cancer diagnosis, prognosis and therapy |
| WO2016149116A1 (en) * | 2015-03-13 | 2016-09-22 | University Of Maryland, Baltimore | Antibodies targeting s100b and methods of use |
| EP3273994B1 (en) * | 2015-03-27 | 2021-12-01 | University of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| WO2016199097A1 (en) * | 2015-06-10 | 2016-12-15 | National Research Council Of Canada | Carbonic anhydrase ix-specific antibodies and uses thereof |
| WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| US10766957B2 (en) | 2015-08-14 | 2020-09-08 | Merck Sharp & Dohme Corp | Anti-TIGIT antibodies |
| CN108699145A (zh) * | 2015-09-02 | 2018-10-23 | 伊缪泰普有限公司 | 抗lag-3抗体 |
| CN116440279A (zh) | 2015-09-17 | 2023-07-18 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| CA3004498A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Amyloid beta epitopes and antibodies thereto |
| AU2016354688B2 (en) | 2015-11-09 | 2021-12-16 | The University Of British Columbia | Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto |
| CN108350051A (zh) | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 |
| WO2017083582A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| CA3018058A1 (en) * | 2016-03-16 | 2017-09-21 | Richard A. Shimkets | Neutralizing monoclonal antibodies to il-25 and uses thereof |
| US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
| WO2017218691A1 (en) | 2016-06-16 | 2017-12-21 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd81 |
| EP3484919A4 (en) * | 2016-07-18 | 2020-03-04 | The University of British Columbia | ANTI-BETA-AMYLOID ANTIBODIES |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CN108367075B (zh) * | 2016-11-23 | 2022-08-09 | 免疫方舟医药技术股份有限公司 | 4-1bb结合蛋白及其用途 |
| CN106749657A (zh) * | 2016-12-13 | 2017-05-31 | 中国农业科学院哈尔滨兽医研究所 | 一种抗体信号肽及其应用 |
| WO2018156434A1 (en) * | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tim3-binding chimeric antigen receptors |
| CN110392697A (zh) * | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
| KR20240044544A (ko) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| WO2018184558A1 (zh) * | 2017-04-05 | 2018-10-11 | 凯惠科技发展(上海)有限公司 | 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用 |
| CA3070100A1 (en) * | 2017-07-17 | 2019-01-24 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type iii domains and methods of using the same |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| SI3672631T1 (sl) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu |
| TW202003576A (zh) * | 2018-05-10 | 2020-01-16 | 美商艾博視訊有限公司 | 活化cd40之單株抗體及其用途 |
| WO2019231957A1 (en) * | 2018-05-30 | 2019-12-05 | National Health Research Institutes | Anti-abeta antibodies and uses thereof |
| BR112020025439A2 (pt) | 2018-06-14 | 2021-03-16 | Bluebird Bio, Inc. | Receptores de antígenos quiméricos cd79a |
| TWI865456B (zh) * | 2018-07-09 | 2024-12-11 | 大陸商沐特圖公司 | 葉酸受體阿法特異性抗體 |
| KR20210060477A (ko) * | 2018-09-17 | 2021-05-26 | 압큐로, 인크. | 항-klrg1 항체 |
| CN113508137B (zh) * | 2019-01-29 | 2024-12-20 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
| WO2020180706A1 (en) * | 2019-03-02 | 2020-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic antigen binding proteins specific for cd93 and methods of use thereof |
| WO2020193644A1 (en) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| CN110343180B (zh) * | 2019-07-25 | 2021-03-30 | 北京免疫方舟医药科技有限公司 | 抗ctla-4抗体及其应用 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN111808191A (zh) * | 2020-05-11 | 2020-10-23 | 廊坊天光生物技术有限公司 | 一种用于检测血清中vegf含量的抗体对及其用途 |
| CN111793136A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种nmp22抗体对及其应用 |
| WO2021231982A1 (en) * | 2020-05-14 | 2021-11-18 | City Of Hope | Smc1a antibodies and uses thereof |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| CA3183835A1 (en) | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| EP4192501A1 (en) * | 2020-08-04 | 2023-06-14 | Exelixis, Inc. | Cd47 binding agents and uses thereof |
| CA3189666A1 (en) | 2020-08-18 | 2022-02-24 | William Jason Cummings | Monoclonal antibodies, compositions and methods for detecting complement factor d |
| CN112778419A (zh) * | 2021-02-01 | 2021-05-11 | 重庆中元汇吉生物技术有限公司 | 抗ck-mb的抗体或其抗原结合部分及其应用 |
| WO2022174103A2 (en) * | 2021-02-11 | 2022-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for human ror1 |
| CN113075398A (zh) * | 2021-03-23 | 2021-07-06 | 中国医学科学院输血研究所 | 一种血浆中特异性IgG抗体的定量测定方法 |
| WO2023076926A1 (en) * | 2021-10-26 | 2023-05-04 | Bach Diagnostics Inc. | Lateral flow assay for the diagnosis of dermatmycoses |
| KR20250102074A (ko) * | 2022-11-08 | 2025-07-04 | 페인스 테라퓨틱스 인코포레이티드 | 항-5t4 항체 및 이의 용도 |
| US20240247077A1 (en) * | 2023-01-23 | 2024-07-25 | Clemson University Research Foundation | Cyp1a1-targeted monoclonal antibody with reactivity across vertebrate taxa |
| EP4655320A1 (en) * | 2023-01-27 | 2025-12-03 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions for treating tauopathies and methods of use thereof |
| IL322621A (en) * | 2023-02-28 | 2025-10-01 | Mayo Found Medical Education & Res | Molecules that bind to B-cell activating factor receptor polypeptides |
| CN119306826B (zh) * | 2023-07-11 | 2025-06-20 | 东莞市朋志生物科技有限公司 | 抗白介素-6抗体、检测白介素-6的试剂和试剂盒 |
| WO2025044931A1 (zh) * | 2023-08-25 | 2025-03-06 | 康诺亚生物医药科技（成都）有限公司 | 阿尔茨海默病治疗剂的开发和应用 |
| CN119613538B (zh) * | 2024-12-12 | 2025-10-17 | 浙江大学医学院附属第一医院(浙江省第一医院) | 抗h10亚型流感病毒血凝素蛋白中和性单克隆抗体1e10及其应用 |
| CN120209138B (zh) * | 2025-05-29 | 2025-10-03 | 杭州广科安德生物科技有限公司 | Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| AUPR617901A0 (en) | 2001-07-06 | 2001-08-02 | Pacmab Pty Ltd | Method for treating multiple myeloma |
| DE60226036T9 (de) | 2001-08-03 | 2016-09-29 | Medical & Biological Laboratories Co., Ltd. | ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8394379B2 (en) | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
| AU2005269940A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta) |
| US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
| WO2006055178A2 (en) * | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
| WO2006066171A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
| WO2006083533A2 (en) | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| EP1841455A1 (en) * | 2005-01-24 | 2007-10-10 | Amgen Inc. | Humanized anti-amyloid antibody |
| US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
| KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
| US7741448B2 (en) | 2005-06-21 | 2010-06-22 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
| EP1749839A1 (en) | 2005-07-22 | 2007-02-07 | Novoplant GmbH | Antigen binding polypeptides against F4(K88) fimbriae |
| BRPI0709050B1 (pt) | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| US20090232801A1 (en) | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| SG185316A1 (en) * | 2007-10-19 | 2012-11-29 | Immunas Pharma Inc | ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF |
| US20100291071A1 (en) | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
| CA2709354C (en) | 2007-12-21 | 2014-06-17 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| CA2714413C (en) | 2008-02-08 | 2017-01-24 | Immunas Pharma, Inc. | Antibody capable of binding specifically to ab-oligomer, and use thereof |
| US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
| JP5812418B2 (ja) | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| ES2614949T3 (es) | 2009-08-06 | 2017-06-02 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos |
-
2010
- 2010-08-05 JP JP2012505917A patent/JP5769316B2/ja not_active Expired - Fee Related
- 2010-08-05 CN CN201080045242.2A patent/CN102574915B/zh not_active Expired - Fee Related
- 2010-08-05 DK DK10806238.1T patent/DK2462161T3/en active
- 2010-08-05 ES ES10806238.1T patent/ES2624835T3/es active Active
- 2010-08-05 EP EP10806238.1A patent/EP2462161B1/en not_active Not-in-force
- 2010-08-05 US US13/389,229 patent/US8858949B2/en active Active
- 2010-08-05 WO PCT/JP2010/004925 patent/WO2011016238A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN102574915B (zh) | 2014-10-22 |
| CN102574915A (zh) | 2012-07-11 |
| EP2462161B1 (en) | 2017-03-08 |
| DK2462161T3 (en) | 2017-06-06 |
| JP5769316B2 (ja) | 2015-08-26 |
| EP2462161A1 (en) | 2012-06-13 |
| US20120177664A1 (en) | 2012-07-12 |
| US8858949B2 (en) | 2014-10-14 |
| WO2011016238A1 (en) | 2011-02-10 |
| EP2462161A4 (en) | 2013-05-29 |
| JP2013500941A (ja) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2624835T3 (es) | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos | |
| ES2614949T3 (es) | Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos | |
| US9090679B2 (en) | Antibodies that specifically bind to A beta oligomers and use thereof | |
| US9090680B2 (en) | Antibodies that specifically bind to abeta oligomers and uses thereof | |
| US11779629B2 (en) | Compositions comprising cyclic peptides derived from an A-beta peptide | |
| US12071472B2 (en) | Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers | |
| CA2702880A1 (en) | Antibody capable of specifically binding to a beta oligomer, and use thereof | |
| WO2011045945A1 (ja) | アミロイドβのターン構造を認識する抗体 | |
| US9085614B2 (en) | Antibodies that specifically bind to Aβ oligomers and uses thereof |